MSI-H status has significant clinical implications, especially in guiding treatment decisions. Tumors with MSI-H tend to have a better prognosis and may respond differently to certain therapies. For instance, MSI-H colorectal cancers are less likely to benefit from 5-fluorouracil-based chemotherapy but may respond well to immunotherapy with checkpoint inhibitors, such as pembrolizumab and nivolumab.
